Peripheral blood protein profiling in DLBCL

Quantification of 81 proteins in serum or plasma from 19 healthy blood donors and two cohorts of patients diagnosed with diffuse large B-cell lymphoma (DLBCL). The purpose of this study was to identify protein profiles associated with survival in DLBCL.

The Oslo cohort comprises 51 patients, of which 18 were sampled both before and after treatment with Rituximab and chemotherapy, while the rest of the patients were only sampled before treatment. The St. Louis cohort comprises 60 patients, all of which were sampled before initiation of treatment. While EDTA plasma was sampled in the St. Louis cohort, the material obtained from healthy donors and patients in the Oslo cohort was serum. Because of this difference, data from the St. Louis cohort should not be directly compared to the data from healthy donors and Oslo cohort patients.

The Normalized Protein eXpression (NPX) unit is used for all values. For this reason, values from different proteins cannot be compared. Please refer to the referenced published article for technical details, clinical information and interpretation. Data is supplied in Microsoft Excel format and as comma-separated values (CSV) files.

本数据集对19位健康献血者的血清或血浆中的81种蛋白质进行了量化分析，并针对被诊断为弥漫性大B细胞淋巴瘤（DLBCL）的两个队列进行了研究。研究旨在识别与DLBCL患者生存相关的蛋白质谱。奥斯陆队列包括51名患者，其中18名患者在接受利妥昔单抗和化疗前后均进行了采样，其余患者仅在治疗前进行了采样。圣路易斯队列包括60名患者，所有患者均在开始治疗前进行了采样。尽管圣路易斯队列中采集了EDTA血浆，但奥斯陆队列中健康捐赠者和患者的样本为血清。由于这种差异，圣路易斯队列的数据不应直接与健康捐赠者和奥斯陆队列患者的数据进行比较。所有数值均采用标准化蛋白质表达（NPX）单位，因此不同蛋白质的数值无法进行比较。请参阅相关已发表文章以获取技术细节、临床信息和解读。数据以Microsoft Excel格式和逗号分隔值（CSV）文件形式提供。